BioCentury
ARTICLE | Product Development

ESMO shifts the HER2 antibody landscape 

How next-gen antibody innovation is driving advances in HER2-positive cancers

September 24, 2021 11:01 PM UTC

HER2 may be one of oncology’s oldest drug targets, but it was a centerpiece of this year’s ESMO Congress, returning to the spotlight as one of the hottest testing grounds for ...



Access this Article